ERBB2 and chordoma: In contrast, a small non‐randomised phase II clinical trial with the FDA‐approved dual EGFR/ERBB2 inhibitor lapatinib (Tykerb®/Tyverb®), involving 18 patients with advanced chordoma, showed only a modest clinical success with partial intratumoural response in six of 18 patients, according to Choi 76.